Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicine, announced that CEO John Evans will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicine, announced that CEO John Evans will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET. The conference runs from June 2-4, 2020. The presentation will be available via live webcast on the company's investor website, with an archive accessible for 60 days post-event. Beam Therapeutics focuses on base editing technology, creating precise genetic modifications without double-stranded DNA breaks, aiming to provide lasting solutions for serious diseases.
Details
News Market Reaction – BEAM
The recorded move for BEAM in the trading session of this news was -5.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. ET. The conference is being held virtually from June 2-4, 2020.
The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com.
Contacts:
Investors:
Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.